We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




How Ibogaine Reverses Alcohol Addiction

By Biotechdaily staff writers
Posted on 03 Feb 2005
Researchers using rodent models have found that the controversial drug ibogaine reverses alcohol addiction by increasing the level of the protein GDNF (glial cell line-derived neurotrophic factor) in the ventral tegmental area of the brain. More...


Ibogaine, which is extracted from a West African shrub, has been shown to reverse addiction to alcohol and some drugs, but potentially serious side effects have prevented its widespread acceptance.

In a paper published in the January 19, 2005, issue of The Journal of Neuroscience, investigators at the University of California (San Francisco, USA) showed that ibogaine acted specifically on the ventral tegmental area of the brain. After injecting the drug into the brains of rats, the investigators found that loss of craving for alcohol was accompanied by an increase in the level of GDNF expressed by cells in the ventral tegmental area. Treating the animals with specific antibodies to prevent GDNF expression reversed the anti-addictive action of ibogaine, and direct injection of GDNF prevented addiction in the same manner as injection of ibogaine.

"By identifying the brain protein that ibogaine regulates to reduce alcohol consumption in rats, we have established a link between GDNF and reversal of addiction--knowledge of a molecular mechanism that should allow development of a new class of drugs to treat addiction without ibogaine's side effects,” said senior author Dr. Dorit Ron, associate professor of neurology at the University of California, San Francisco. "If we can alter the GDNF pathway, we may well have a new treatment against alcohol and drug addiction without the unwanted side effects of ibogaine.”



Related Links:
University of California, San Francisco

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
HPV Test
Allplex HPV28 Detection
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.